Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin
about
Rapamycin and rapalogs for tuberous sclerosis complexRapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysisOptimizing biologically targeted clinical trials for neurofibromatosis.Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.Targeted topical and combination laser surgery for the treatment of angiofibromas.Treatment of nodular facial angiofibromas in tuberous sclerosis, using ultrapulse carbon dioxide laser.Facial angiofibromas of tuberous sclerosis treated with topical sirolimus in an Indian patient.Use of Topical Rapamycin in Facial Angiofibromas in Indian Skin TypeTreatment of port wine stains using Pulsed Dye Laser, Erbium YAG Laser, and topical rapamycin (sirolimus)-A randomized controlled trial.Analysis of a Mouse Skin Model of Tuberous Sclerosis Complex.Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role.Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.Advances in the treatment of neurofibromatosis-associated tumours.Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.Tuberous Sclerosis Complex: An Update for Dermatologists.Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review.mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.Rapamycin modulation of p70 S6 kinase signaling inhibits Rift Valley fever virus pathogenesis.Infantile Periocular Hemangioma.Dermatological manifestations of tuberous sclerosis complex (TSC).Genetic Testing in Dermatology: A Survey Analyzing Obstacles to Appropriate Care.Dermatologische Manifestationen der tuberösen Sklerose (TSC).Caveat mTOR: aberrant signaling disrupts corticogenesis.Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up.Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex.A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.Long-term treatment of epilepsy with everolimus in tuberous sclerosis.Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex.Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.Tuberous sclerosis complex: review based on new diagnostic criteria.Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial
P2860
Q26471128-C99AEC76-74C8-41F0-AC1C-B14F8F0AFF4BQ26799757-A4E32C94-FB64-4840-A5A2-5873400108EBQ30438898-61C50108-498B-4068-B119-BA44346EDA95Q33757948-B23827E5-BC05-4304-8417-3A741BD386ABQ34436120-B27EE57E-DD97-4244-9442-A1F613F03D82Q35020019-B30397D0-5F60-4531-9103-A870208CC64EQ35180354-7E629E20-8359-4427-B85E-03B41E786860Q35215201-EB6798F7-25C0-473E-BCAA-1CC17DDDE482Q35948437-C65DC5AB-9CF3-43A1-AFD3-66E61D5EEC9AQ36056423-24476030-7957-48ED-8505-3ABE4A6669E9Q36210035-17AB80C0-23EA-4B3A-B7BF-7D303D827973Q36250754-7E9FB61B-1E86-436B-8909-69BAF93C13B0Q36326114-689788B5-2700-49D0-A8F0-CD93C6C55C42Q37721031-32514951-D6AB-4327-8ECD-E8B0FABDE5C1Q38128516-21D34A39-BC36-47C3-998D-BC701D0A3D77Q38173013-495540CC-1754-4B0D-982A-79F96CA50F0DQ38379999-C5081DF1-0210-40AE-AE74-56B3C37CC080Q38592323-C1636128-07EC-488F-982B-4D4394E889EBQ38723770-EE231127-8CF7-49FF-ACB7-65BCFAE78363Q38798392-215B0A99-9298-4A84-A4CE-D3D5F9A272B3Q38820203-E10369B1-1BBE-4B1B-9BC6-92D19F184380Q39327604-AEF257B6-FDEF-481E-9D52-5FFC12583A41Q39362117-80885620-2F6E-4B12-B9E6-D5A73B1080CEQ39366341-29DE0994-A7B5-4AD0-B7B8-1105D5D903F7Q39414530-F0F07DE5-997D-4E2C-A3B9-71CD54E62FE3Q40239029-36112C2C-B5D6-4B2A-93D5-1A108024B3AAQ41990498-952E4414-D48D-4B8F-AB03-E8DC32978E8BQ43814142-8F4D7585-572F-42CD-B3B6-1F7318DFE70FQ46433164-B82FEBDC-6E06-4F91-9B13-6DB8936DF5ADQ46836536-1F1EE234-7D24-4500-B718-5C69075D1FAFQ47139666-2EDCDCD1-02EA-4FD2-BB22-9C97B50597F0Q48297402-366C2620-6914-4172-BB40-4F290D9B7755Q55277251-00AFC696-A378-4C05-BEDE-B38B1BEC6FAAQ57178617-A103B5CF-D25E-47FC-99CA-097248DD75B3
P2860
Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Topical rapamycin therapy to a ...... of topically applied rapamycin
@ast
Topical rapamycin therapy to a ...... of topically applied rapamycin
@en
type
label
Topical rapamycin therapy to a ...... of topically applied rapamycin
@ast
Topical rapamycin therapy to a ...... of topically applied rapamycin
@en
prefLabel
Topical rapamycin therapy to a ...... of topically applied rapamycin
@ast
Topical rapamycin therapy to a ...... of topically applied rapamycin
@en
P2093
P2860
P1433
P1476
Topical rapamycin therapy to a ...... of topically applied rapamycin
@en
P2093
Adelaide A Hebert
Audrey Woerner
Hope Northrup
Joan Roberson
John Slopis
Mary Kay Koenig
P2860
P304
P356
10.2165/11634580-000000000-00000
P577
2012-09-01T00:00:00Z